{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:16Z","timestamp":1792790476986,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC2407303"],"award-info":[{"award-number":["2022YFC2407303"]}]},{"name":"Research Center for Lung Tumor Diagnosis and Treatment of Zhejiang Province","award":["JBZX-202007"],"award-info":[{"award-number":["JBZX-202007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03417-8","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:33:04Z","timestamp":1732847584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of efficacy and safety of neoadjuvant immunochemotherapy in young and elderly patients with IIA\u2013IIIB non-small-cell lung cancer in real-world practice"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiacong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinghui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"issue":"4","key":"3417_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccm.2011.08.005","volume":"32","author":"WD Travis","year":"2011","unstructured":"Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32(4):669\u201392.","journal-title":"Clin Chest Med"},{"issue":"21","key":"3417_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"6","key":"3417_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, et al. Perioperative Nivolumab and Chemotherapy in Stage III Non-small-cell Lung Cancer. N Engl J Med. 2023;389(6):504\u201313.","journal-title":"N Engl J Med"},{"issue":"3","key":"3417_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.bj.2020.07.009","volume":"44","author":"C Granier","year":"2021","unstructured":"Granier C, Gey A, Roncelin S, Weiss L, Paillaud E, Tartour E. Immunotherapy in older patients with cancer. Biomed J. 2021;44(3):260\u201371.","journal-title":"Biomed J"},{"issue":"1","key":"3417_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00281-018-0697-6","volume":"41","author":"G Pawelec","year":"2019","unstructured":"Pawelec G. Does patient age influence anti-cancer immunity? Semin Immunopathol. 2019;41(1):125\u201331.","journal-title":"Semin Immunopathol"},{"issue":"2","key":"3417_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000355303","volume":"60","author":"A Jagger","year":"2014","unstructured":"Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology. 2014;60(2):130\u20137.","journal-title":"Gerontology"},{"key":"3417_CR7","doi-asserted-by":"publisher","first-page":"101275","DOI":"10.1016\/j.smim.2019.04.003","volume":"40","author":"LGPL Prata","year":"2018","unstructured":"Prata LGPL, Ovsyannikova IG, Tchkonia T, Kirkland JL. Senescent cell clearance by the immune system: emerging therapeutic opportunities. Semin Immunol. 2018;40:101275.","journal-title":"Semin Immunol"},{"issue":"1","key":"3417_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage classification. Chest. 2017;151(1):193\u2013203.","journal-title":"Chest"},{"issue":"2","key":"3417_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"3417_CR10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"issue":"22","key":"3417_CR11","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-small-cell Lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"7","key":"3417_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3417_CR13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Advanced squamous NSCLC (IMpower131): results from a Randomized Phase III Trial. J Thorac Oncol. 2020;15(8):1351\u201360.","journal-title":"J Thorac Oncol"},{"key":"3417_CR14","doi-asserted-by":"crossref","unstructured":"Zhou C, Chen G, Huang Y et al. Camrelizumab pluscarboplatin and pemetrexed versus chemotherapyalone in chemotherapy-naive patients with advancednon-squamous non-small-cell lung cancer(Camel): arandomised, open-label, multicentre, phase 3 trial[ J]Lancet Respir Med,2021,9 (3): 305\u201314.","DOI":"10.1016\/S2213-2600(20)30365-9"},{"issue":"4","key":"3417_CR15","doi-asserted-by":"publisher","first-page":"S748","DOI":"10.1016\/S1556-0864(21)01938-9","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Ren S, Chen J, et al. 960 Camrelizumab orplacebo plus carboplatin and paclitaxel as first-linetreatment for advanced squamous NSCLC (Camelsq): a randomized, double-blind, multicenter, phasel trial[J]. J Thorac Oncol. 2021;16(4):S748.","journal-title":"J Thorac Oncol"},{"key":"3417_CR16","doi-asserted-by":"crossref","unstructured":"First-line immune. Checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057). Abstract 9012, Rapid Abstract Session, 2023 ASCO.","DOI":"10.1200\/JCO.2023.41.16_suppl.9012"},{"issue":"33","key":"3417_CR17","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/JCO.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse DM, Garon EB, Chandler J, et al. Continuous versus 1-Year fixed-duration nivolumab in previously treated Advanced Non-small-cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020;38(33):3863\u201373.","journal-title":"J Clin Oncol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03417-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T03:02:06Z","timestamp":1732849326000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03417-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3417"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03417-8","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"6 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (2021 IIT No. 844), and done in accordance with the Declaration of Helsinki (as revised in 2013) and Good Clinical Practice Guidelines. Written informed consent was obtained from patients so that we could acquire and use required information from their medical record in our hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"592"}}